Actively Recruiting

Age: 18Years +
All Genders
ID07589413

A Predictive Model for Recurrence and Progression Risk After TURBT for Bladder Cancer Based on Intraoperative Irrigation Fluid Absorption Volume and Perioperative cfDNA Levels

Led by Zhiping Wang · Updated on 2026-05-15

150

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the relationship between the amount of irrigation fluid absorbed during transurethral resection of bladder tumor (TURBT) surgery and changes in cell-free DNA (cfDNA) levels in patients with suspected or confirmed bladder cancer. This observational study aims to understand how intraoperative fluid absorption might influence tumor-related molecular changes and postoperative outcomes such as recurrence and progression. Participants scheduled for TURBT will have their irrigation fluid absorption volume measured during surgery using a dedicated system. Blood samples will be collected before and within 24 hours after surgery to analyze cfDNA levels and tumor-related mutations. Tumor tissue mutation status will also be assessed when available. This study does not involve changes to standard treatment and focuses on data collection and analysis. Participants will be followed postoperatively for oncological outcomes including recurrence, progression, and metastasis. Researchers will collect clinicopathological data, operative details, and cfDNA results to evaluate associations. The primary outcome is the change in plasma cfDNA level from before to within 24 hours after TURBT. Secondary outcomes include detection rates of tumor-related mutations and links to tumor characteristics. The study will help improve understanding of perioperative molecular changes and support better risk assessment and follow-up strategies for bladder cancer patients.

CONDITIONS

Brief Title

Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Suspected or confirmed urothelial carcinoma of the bladder
  • Scheduled to undergo transurethral resection of bladder tumor (TURBT)
  • Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis
  • Availability of complete clinicopathological and perioperative data
  • Ability to provide informed consent and comply with study follow-up
Not Eligible

You will not qualify if you...

  • Non-urothelial bladder malignancy confirmed by pathology
  • History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix
  • Previous radical cystectomy or systemic antitumor therapy before enrollment
  • Inadequate blood sample quality or insufficient DNA yield for mutation analysis
  • Pregnancy or breastfeeding
  • Serious uncontrolled illness that may interfere with study participation or compliance, including active infection, symptomatic heart failure, unstable angina, significant arrhythmia, or severe psychiatric illness

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Day of surgery and within 24 hours after surgery

Participants undergo transurethral resection of bladder tumor (TURBT) during which irrigation fluid absorption volume is measured and blood samples are collected for cfDNA analysis.

1 surgery visit and 1 post-surgery visit within 24 hours

Long-term Monitoring

Duration - Up to several years after surgery

Participants are followed after surgery to assess postoperative recurrence, progression, metastasis, and other oncological outcomes.

Follow-up visits per routine clinical care

Trial Site Locations

Total: 1 location

1

The Second Hospital of Lanzhou University

Lanzhou, Gansu, China, 730030

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

COBRA - Chemoablation for Low Grade Bladder Cancer: A Single...

Bladder (Urothelial, Transitional Cell) Cancer

Actively Recruiting

1 location

Effectiveness of a Personalized 6-month Programme on Frailty...

Bladder (Urothelial, Transitional Cell) Cancer

Actively Recruiting

2 locations

Bladder Microbiota and Bladder Cancer: Study of Microbial Bi...

Bladder (Urothelial, Transitional Cell) Cancer

Actively Recruiting

8 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here